Skip to main content

Table 1 Characteristics of included studies

From: Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis

Study ID (Trial registration)

Study design

Number randomized

Age of included women

Trial arms

Duration of treatment (months)

Outcomes reported

Country

Burke 2018 NCT02293694

Open-label, parallel group, randomized clinical trial

731

18–40

Participants were randomized in a 1:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg

12

Continuation, satisfaction, failure (unintended pregnancy), side effects

Malawi

Kohn 2018 NCT02509767

Multicenter, open label, randomized parallel group clinical trial

401

15–44

Participants were randomized in a 1:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg

12

Continuation, satisfaction, failure (unintended pregnancy), side effects

USA

Beasley 2014 NCT01019369

Open label, parallel group, randomized clinical trial

132

18 or greater

Participants were randomized in a 2:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg

12

Continuation, satisfaction, side effects

USA